FindTrial
Sign In

A study on stomach and gut side effects from high doses of a cancer drug in patients getting treatment to replace damaged blood cells ? done at a large hospital in South India

Evaluation of Gastrointestinal Toxicity Associated with High dose Melphalan in patients undergoing Autologous Stem Cell Transplantation - An observational study in a tertiary centre in South India. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/093394
Enrollment
35
Registered
2025-08-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C900- Multiple myeloma

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Kasturba Medical olege
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed with hematologic malignancy . Planned to receive high dose melphalan (140-200 mg/m2) as conditioning for ASCT. Willing and able to provide written informed consent.

Exclusion criteria

Exclusion criteria: Prior ASCT or allogenic stem cell transplantation. Pre-existing severe GI conditions. Concurrent chemotherapy known to cause GI toxicity during the course of treatment. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Gastrointestinal toxicity and improve patients outcome during and after transplantation Timepoint: Baseline, day0, day 7 , day 14—

Secondary

MeasureTime frame
Toxicity monitoring and supportive care for the patient. Overall management strategies to be estimated.Timepoint: At the time of discharge—

Countries

India

Contacts

Public ContactAkritee Vijay Yadav

Kasturba Medical College Manipal

meena.kumari@manipal.edu9886367003

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026